Boundless Bio, INC 8-K filings

Boundless Bio's annual meeting saw the election of directors and ratification of its auditor, KPMG LLP.

Boundless Bio announced its first quarter 2026 financial results, highlighting progress in its KOMODO-1 clinical trial for BBI-940 and a cash runway extending into the second half of 2028.

Boundless Bio, Inc. has terminated its lease for approximately 80,168 square feet of laboratory and office space, effective May 31, 2026, incurring a $10.0 million lease modification payment and forfeiting a $0.5 million security deposit.

Boundless Bio announced its third quarter 2025 financial results, highlighting ongoing clinical trial enrollment and progress towards a new drug submission, supported by a cash runway into the first half of 2028.

Boundless Bio reported a reduced net loss in Q2 2025, alongside progress in its POTENTIATE clinical trial and BBI-940 development, with cash supporting operations into H1 2028.

Boundless Bio, Inc. announced that its stockholders elected two Class I directors and ratified KPMG LLP as its independent registered public accounting firm for 2025 at the annual meeting held on June 23, 2025.

Boundless Bio, Inc. announced a significant portfolio prioritization, including a workforce reduction of approximately one-third and the discontinuation of current BBI-355 clinical trials, to extend its operating runway into the first half of 2028.

Boundless Bio reports its Q1 2025 financial results, highlighting a $138 million cash position and progress in its BBI-355 and Kinesin programs.

Boundless Bio has entered into an agreement with Jefferies LLC to sell up to $14.5 million of its common stock through an at-the-market offering.

Boundless Bio reports its financial results for Q4 and full year 2024, highlighting progress in its clinical and preclinical programs targeting oncogene amplified cancers.

Boundless Bio has updated its pipeline, discontinuing one trial, advancing another, and announced leadership changes, while extending its operating runway into 2027.

Boundless Bio announced its third quarter 2024 financial results, highlighting progress in clinical trials and a cash runway into the fourth quarter of 2026.

Boundless Bio's Chief Financial Officer, Jami Rubin, has stepped down, and David Hinkle has been appointed as Treasurer, principal financial officer, and principal accounting officer.

Boundless Bio has repriced stock options for certain employees, including named executive officers, to retain talent without increasing dilution or cash expenditures.

Boundless Bio announced its second quarter 2024 financial results, provided updates on its clinical trials, and outlined strategic priorities, including extending its operating runway into the fourth quarter of 2026.

Boundless Bio announced its first quarter 2024 financial results, highlighted by the advancement of its clinical trials for BBI-355 and BBI-825 and a successful $100 million IPO.

Boundless Bio successfully closed its initial public offering (IPO) and implemented changes to its certificate of incorporation and bylaws.